Home / Current Issue / Paper 1708509
The Role of SGLT-1 Inhibitors in Weight Management for Diabetic Patients
Subject area: Science,Engineering and Technology · Area of research: Medicine and Healthcare
Abstract
Sodium glucose co-transporter-1 inhibitors were initially used to treat type-2 diabetes but have now emerged as potential candidates in the field of weight management in diabetic patients. The inhibitors when blocking the SGLT-1 transporter in the jejunum and ileum decrease the absorption of glucose conversely, stimulation of a higher excretion of glucose via urine. When considered an extremely important player in the glycemic control, it is equally important in beings an agent of weight reduction. Weight reduction is vital for metabolic control and minimization of complications since obesity is one of the known comorbidities affecting type-2 diabetic patients. Weight loss elicited by SGLT-1 inhibitors is believed to involve mechanisms other than glucose regulation, including appetite suppression and elevation of insulin sensitivity. This article will discuss how SGLT-1 inhibitors pharmacologically impact body weight and put in perspective mechanisms that should be made pertinent in weight loss for diabetic patients in clinical practice. Further, we shed light on the safety aspect of SGLT-1 inhibitors and equip readers with inputs for consideration with regard to their role in integrated weight management strategies for diabetes care.
How to cite this paper
@article{1708509,
author = {Khashayar Mohammadi},
title = {The Role of SGLT-1 Inhibitors in Weight Management for Diabetic Patients },
journal = {Iconic Research And Engineering Journals},
year = {2025},
volume = {8},
number = {11},
pages = {1866-1875},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1708509.pdf},
abstract = {Sodium glucose co-transporter-1 inhibitors were initially used to treat type-2 diabetes but have now emerged as potential candidates in the field of weight management in diabetic patients. The inhibitors when blocking the SGLT-1 transporter in the jejunum and ileum decrease the absorption of glucose conversely, stimulation of a higher excretion of glucose via urine. When considered an extremely important player in the glycemic control, it is equally important in beings an agent of weight reduction. Weight reduction is vital for metabolic control and minimization of complications since obesity is one of the known comorbidities affecting type-2 diabetic patients. Weight loss elicited by SGLT-1 inhibitors is believed to involve mechanisms other than glucose regulation, including appetite suppression and elevation of insulin sensitivity. This article will discuss how SGLT-1 inhibitors pharmacologically impact body weight and put in perspective mechanisms that should be made pertinent in weight loss for diabetic patients in clinical practice. Further, we shed light on the safety aspect of SGLT-1 inhibitors and equip readers with inputs for consideration with regard to their role in integrated weight management strategies for diabetes care.},
month = {May},
}